Commentary: Should all cancer patients be tested for COVID-19 before each chemotherapy cycle?

J Oncol Pharm Pract. 2021 Mar;27(2):450-452. doi: 10.1177/1078155220988753. Epub 2021 Jan 20.

Abstract

Cancer patients under active chemotherapy are more vulnerable to coronavirus disease 19 (COVID-19). There are still some controversies regarding routine polymerase chain reaction testing of asymptomatic cancer patients before chemotherapy cycles. Despite a lack of data, Al-Shamsi et al. showed higher COVID-19 positivity rate among asymptomatic cancer patients. Furthermore, mortality rate was higher in this group of patients. There is no high evidence-based recommendation from the cancer societies for testing asymptomatic patients before each chemotherapy cycle. In this commentary, we assessed the current publications and guidelines regarding this issue.

Keywords: COVID-19; cancer; chemotherapy.

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • COVID-19 / complications
  • COVID-19 Testing*
  • Evidence-Based Medicine
  • Guidelines as Topic
  • Humans
  • Neoplasms / complications*
  • Neoplasms / drug therapy*

Substances

  • Antineoplastic Agents